This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Tubulin	<p>Total synthesis of celogentin C could help generate cancer therapeutics. Celogentin C, a derivative of plumed cockscomb (<i>Celosia argentea</i>) seeds, inhibits tubulin polymerization. Ongoing work includes evaluating the anticancer properties of the compound.</p> <p>Eisai Co. Ltd.'s eribulin mesylate, which targets tubulin polymerization, is in Phase III testing to treat breast cancer and Phase II testing for prostate cancer and non-small cell lung cancer (NSCLC).</p> <p>SciBX 2(27); doi:10.1038/scibx.2009.1072 Published online July 16, 2009</p>	Provisional patent application filed covering celogentin C for anticancer activity; celogentin C will be available for licensing for anticancer activity	<p>Ma, B. <i>et al. Angew. Chem. Int. Ed.</i>; published online June 24, 2009; doi:10.1002/anie.200902425</p> <p>Contact: Steven L. Castle, Brigham Young University, Provo, Utah e-mail: scastle@chem.byu.edu</p>